Bausch + Lomb Posts Q1-2017 Revenues of $1.15 Billion in ‘Solid Quarter’

May 12, 2017: By Joan McKenna

BauschBausch + Lomb posted flat revenues of $1.15 billion on a reported basis (+4 percent in constant currency) in Q1-2017 and provided parent Valeant Pharmaceuticals with a “solid quarter,” company officials announced May 9.

The eye care segment’s revenues accounted for more than half of Valeant’s $2.1 billion in revenues during the quarter.

Bausch + Lomb, based in Bridgewater, New Jersey, saw a 1 percent increase in revenues over Q1-2016’s  $1.146 billion in revenues.

Paul Herendeen, chief financial officer, said Bausch + Lomb’s global ophthalmic pharmaceutical revenues were up 1 percent (+3 cc), with international units offsetting a slight decline in US units.

The global consumer business showed modest revenue growth, while global surgical and vision care declined, he said. Bausch + Lomb completed its acquisition of retinal device maker Synergetics in October 2015 and saw a subsequent boost in surgical sales due to the deal.

Valeant Chief Executive Joseph Papa said Bausch + Lomb’s positive first quarter resulted in part from price increases of about 1.5 percent.

Valeant said Bausch + Lomb’s PreserVision and Ocuvite are the number one ocular vitamin brands globally, while Biotrue is the number one multipurpose solution brand, and PreserVision AREDS 2 Formula (120 count) is the top selling vitamin item in the US.

Bausch + Lomb’s milestones during the quarter include receiving US FDA 510(k) clearances in April for the Stellaris Elite dual cataract/vitrectomy system and Vitesse hypersonic vitrector. The company has FDA target actions dates for Vyzulta (glaucoma) in August 2017 and Luminesse (eye redness) in December 2017.

Growth was primarily driven by increases in volume outside the US, particularly in Europe, the Middle East, South Africa, Asia, and Australia, of $59 million. This was partially offset by declines in US volume of $10 million.

Volume and pricing gains were partially offset by the unfavorable impact of foreign currencies of $41 million and the impact of divestitures and discontinuations of $21 million.

Valeant’s long-term debt now stands at $28.5 billion, with debt reduction continuing to be a priority. Valeant said it has reduced its principal amount of debt by $3.6 billion since Q1-2016.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022